Phase 4 N=12 Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion
Healthy · Type 2 Diabetes
Primary: Glucagon-like Peptide-1 Secretion After Meal Ingestion — 0.82; 1.24 nmol/l/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=473 An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis
Osteoarthritis
Primary: Change From Baseline in Visual Analogue Scale for Pain (VAS-pain) Score at Week 2 — 71.86; 68.03; -29.721; -21.972 mm — p=<0.05
Phase 4 N=23 Genetic Basis for Variation in the Renal Elimination of Metformin
Other Conditions That May Be A Focus of Clinical Attention
Primary: Renal Clearance of Metformin — 614; 441 mL/min
Phase 4 N=100 The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study
Metabolic Syndrome
Primary: Treatment Difference in (Postprandial-Fasting) FMD — -0.34; -0.43 % (change FMD) — p=0.766
Phase 4 N=39 Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression
Major Depressive Disorder
Primary: Hamilton Depression Rating Scale (HAM-D-17) Scores — 10.64; 13.78 units on a scale
Phase 4 N=20 Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects
Other Conditions That May Be A Focus of Clinical Attention
Primary: Area Under the Curve (AUC) of Blood Concentration-time of Metformin — 9,200; 7,700 hour * µg/L
Phase 4 N=21 The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology
Healthy
Primary: Sitagliptin Monotherapy: Sitagliptin Area Under the Plasma Concentration-time Curve (AUC) From 0 to Infinity — 3638; 3502; 3129 ng*hr/ml — p=0.83
Phase 4 N=35 Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) Score — -7.5 Scores on a scale
Phase 4 N=10 Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
Pulmonary Hypertension
Primary: Change in the Distance Transversed During the 6 Minute Walk Test From Baseline to Week 8. — -2.2 meters — p=1.000
Phase 4 N=623 A Study in Erectile Dysfunction
Erectile Dysfunction
Primary: Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week…
Phase 4 N=12 The Effect of Protein on Calcium Absorption and Gastric Acid Production
Osteoporosis
Primary: Percent Change in Intestinal Calcium Absorption — 34.2; 31.5 percentage of calcium absorption
Phase 4 N=516 Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis
Thrombosis
Primary: Major Bleeding — 0 participants
Phase 4 N=289 The Montefiore Metoclopramide Study
Nausea · Extrapyramidal Symptoms
Primary: Nausea Scale — 0; 0; 0; 0 units on a scale
Phase 4 N=296 A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
Infection, Human Immunodeficiency Virus
Primary: Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c)/Milliliter (mL) at the Week 24 Visit: TLOVR Analysis — 86.9; 86.6 percentage of…
Phase 4 N=30 A Study of Teriparatide in Japanese Osteoporosis Patients
Osteoporosis
Primary: Number of Participants With Serum Calcium Level Over 11.0 Milligrams Per Deciliter (mg/dL) — 0; 0 participants